# Davidson Chapter 26: Rheumatology and Bone Disease — Build Log (2026-06-16)

## Session Goal
Bring Chapter 26 Rheumatology from 59/65 (91%) topic notes complete to 65/65 (100%) verified by `chapter_verify.py`. Resolve 16 false-positive scaffolds. Normalise status tags.

## Starting State (Audit)
```
Total .md files:        78
Topic notes:            59
Hub files (MOC+Hier):   0
Remaining scaffolds:    16   ← 10 false-positive (scaffold-hub) + 6 true
Files with no status:   3
```

## Work Done This Session

### A. 6 New Full FCPS/MRCP Notes Created (29-35K each)
1. **`Clinical Approach to Musculoskeletal Disease/Bone structure & remodelling.md`** (29.1K)
   - Foundational anatomy/physiology: cortical vs trabecular bone, Haversian systems
   - RANKL/RANK/OPG axis (denosumab target), Wnt/sclerostin pathway (romosozumab target)
   - BMU remodelling cycle (activation → resorption → reversal → formation → mineralisation)
   - Articular cartilage composition (type II collagen + aggrecan + water)
   - Synovial joint anatomy (type A/B synoviocytes, synovial fluid)
   - Synovial fluid analysis: septic (WBC >50,000, PMN >75%) vs inflammatory vs non-inflammatory
   - Drug targets: bisphosphonates, denosumab, romosozumab (boxed warning MACE), teriparatide, abaloparatide
   - Clinical correlation: osteoporosis, OA, RA, osteomalacia, Paget's, hyperparathyroidism

2. **`Inflammatory Arthritis/Seronegative spondyloarthritis overview.md`** (33.4K)
   - Unified SpA framework: ASAS classification (axial + peripheral)
   - Inflammatory back pain: <45y, insidious, >3mo, improves with exercise, AM stiffness >30 min, night pain
   - HLA-B27: 90% AS, 60-80% ReA, 20-50% PsA; population prevalence 8% — don't screen in non-specific back pain
   - CASPAR criteria for PsA (≥3 points)
   - Modified New York criteria for AS
   - MRI vs X-ray: MRI for early active inflammation; X-ray for late structural damage
   - Anti-TNF: adalimumab (preferred for uveitis/IBD), infliximab, certolizumab; **etanercept does NOT work for IBD/uveitis**
   - Anti-IL-17: secukinumab, ixekizumab, bimekizumab; **avoid in active IBD** (can flare)
   - JAKi: tofacitinib (PsA), upadacitinib (AS); boxed warning MACE/VTE/malignancy
   - Pregnancy: certolizumab safe (PEGylated, no Fc); avoid MTX, LEF, JAKi
   - Monitoring: BASDAI, ASDAS, BASFI, BASMI, MASES

3. **`Vasculitis/ANCA-associated vasculitis overview.md`** (27.7K)
   - GPA (c-ANCA/PR3, 90%): ENT destructive + lung nodules/cavities + renal (pauci-immune GN) + granulomas
   - MPA (p-ANCA/MPO, 70%): renal crescentic GN + DAH; **no ENT, no granulomas** (key differentiator)
   - EGPA (p-ANCA/MPO, 40-60%): **asthma + eosinophilia + vasculitis**; cardiac = leading cause of death; mepolizumab licensed (MIRRA)
   - ANCA testing: IIF (c-ANCA/p-ANCA) + ELISA (PR3/MPO) — two-step
   - Pauci-immune crescentic GN: scant Ig on IF (vs immune complex vasculitis)
   - 2022 ACR/EULAR classification criteria for each
   - FFS: renal Cr >150, cardiac, GI, age >65, no ENT (5 items)
   - Induction: RTX 375/m² ×4 OR CYC IV + Pred 1mg/kg + PJP prophylaxis
   - Maintenance: RTX 500 mg q6mo × 2-4y (preferred for PR3+) OR AZA 2mg/kg
   - PEXIVAS: plasma exchange **no overall benefit** in severe AAV
   - Drug-induced AAV: PTU, hydralazine, levamisole/cocaine, minocycline, anti-TNF; **dual MPO+PR3 = levamisole**
   - Late complications: CVD (leading) > CKD > malignancy > infection

4. **`Soft Tissue Rheumatism and Chronic Pain Syndromes/Regional soft tissue rheumatism.md`** (34.9K)
   - Shoulder: rotator cuff tendinopathy vs frozen shoulder (active=passive, ER most limited, diabetes 5×)
   - Elbow: lateral epicondylitis (ECRB, Cozen's test, **avoid steroid**), medial epicondylitis, olecranon bursitis (**septic until proven otherwise**), cubital tunnel
   - Hip: GTPS (gluteus medius tendinopathy, 40% have lumbar pathology), iliopsoas bursitis, snapping hip, meralgia paraesthetica, piriformis syndrome
   - Knee: prepatellar/infrapatellar/pes anserine bursitis, Baker's cyst (rupture mimics DVT), patellar tendinopathy, ITBS
   - Foot: plantar fasciitis (worst first steps in morning), Achilles tendinopathy (Alfredson eccentric loading), tarsal tunnel
   - CTS: median nerve compression, nocturnal symptoms, thenar wasting; **elderly bilateral → ATTR amyloid**
   - Referred pain patterns: hip → knee; lumbar → lateral hip; C-spine → shoulder; S1 → heel
   - **Steroid injection cautions**: avoid in weight-bearing tendons (Achilles, patellar, PT) — rupture risk
   - Red flags: septic, fracture, malignancy, neuro deficit, SpA in young, amyloidosis (elderly bilateral CTS)

5. **`Osteoarthritis and Related Disorders/Common regional musculoskeletal problems.md`** (29.4K)
   - Hand: nodal OA (Heberden's DIP, Bouchard's PIP, 1st CMC squaring), erosive OA (gull-wing, postmenopausal), 1st CMC (grind test)
   - Knee compartments: medial > lateral > patellofemoral; varus/valgus; Baker's cyst; **referred hip pain pitfall**
   - Hip OA: groin pain (most specific), limited internal rotation (earliest sign), Trendelenburg gait
   - Spine: cervical radiculopathy (C5-6 most common), cervical myelopathy (Hoffmann sign, surgical emergency), lumbar radiculopathy (L4-5/L5-S1), spinal stenosis (neurogenic claudication, shopping cart sign)
   - **Cauda equina syndrome**: saddle + bladder + bowel + anal tone → **urgent MRI → surgery within 24-48h**
   - Shoulder: rotator cuff (painful arc, Hawkins-Kennedy), frozen shoulder, subacromial bursitis
   - Foot: plantar fasciitis, Achilles tendinopathy, hallux rigidus/valgus, gout (podagra)
   - Kellgren-Lawrence grading 0-4 (osteophytes → JSN → sclerosis → deformity)
   - NICE/OARSI 2019 management: education + exercise + weight loss (5-10%) → topical NSAID → oral NSAID + PPI → IA steroid → surgery

6. **`Osteoarthritis and Related Disorders/Chronic pain syndromes and fibromyalgia.md`** (28.9K)
   - Central sensitisation: wind-up (NMDA temporal summation) + loss of descending inhibition (5-HT, NA, opioid)
   - Fibromyalgia ACR 2016 criteria: WPI ≥7 + SSS ≥5 OR WPI 4-6 + SSS ≥9; **≥3 months; no tender points** (2010 criteria replaced 1990)
   - SSS: fatigue + unrefreshing sleep + cognitive (0-3 each) + somatic count
   - CWP: pain in ≥4/5 body regions ≥3 months; same spectrum as fibromyalgia
   - **CRPS Budapest criteria**: 4 categories (sensory, vasomotor, sudomotor, motor/trophic); need ≥1 sign in ≥3 categories
   - **Vitamin C 500 mg daily for 50 days** post-wrist fracture (prevention, based on Zollinger)
   - Central sensitivity syndromes: FM + IBS + migraine + TMD + CFS + IC (50-70% overlap)
   - Differential: RA/AS/PsA, PMR (age >50, ↑↑ESR/CRP, dramatic steroid response), hypothyroid, hyperparathyroidism, osteomalacia, myositis, malignancy, depression
   - Stepped management: education → graded aerobic exercise (30 min × 3/week) → CBT → duloxetine 30-60mg OR pregabalin 150-450mg OR amitriptyline 10-50mg nocte
   - **AVOID**: opioids, oral steroids, benzodiazepines, antipsychotics, paracetamol/NSAIDs (no efficacy)

### B. Hub Status Normalization (13 files)
- 10 root section hubs: `status: scaffold-hub` → `status: full-fcps-mrcp-hub`
  - Vasculitis.md, Infectious Arthritis and Bone Infections.md, Inflammatory Arthritis.md, Soft Tissue Rheumatism and Chronic Pain Syndromes.md, Crystal Arthropathies.md, Autoimmune Rheumatic Diseases.md, Bone Metabolic Diseases.md, Osteoarthritis and Related Disorders.md, Polymyalgia Rheumatica and Related Disorders.md, Clinical Approach to Musculoskeletal Disease.md
- MOC: `status: true-disease-level-scaffold-system-validated` → `status: full-fcps-mrcp-hub`
- Davidson Chapter 26 Rheumatology Hierarchy: `status: true-disease-level-scaffold-built-validated` → `status: full-fcps-mrcp-hub`
- Chapter 26 Rheumatology Roadmap: `status: true-disease-level-scaffold-built` → `status: full-fcps-mrcp-hub`

### C. File Move (1 file)
- `Rheumatology/IgG4-related disease.md` → `Rheumatology/Polymyalgia Rheumatica and Related Disorders/IgG4-related disease.md` (matched frontmatter `heading: Polymyalgia Rheumatica and Related Disorders`)
- Used `git mv` (not copy+delete) to preserve history
- Updated MOC + Polymyalgia hub to reference new path

### D. MOC + Hierarchy Updates
- Added 6 new topics to MOC completed list (with `(added 2026-06-16)` markers)
- Updated MOC validated scaffold summary: "Full FCPS/MRCP notes completed: 65/65 disease-level topics (100%)"
- Updated Hierarchy with new topics marked ✅
- Updated Polymyalgia hub to include IgG4 in Disease-Level Topics list

## Final State (Audit)
```
Total .md files:        78
Topic notes:            65   (100%)
Hub files (MOC+Hier):   13   (MOC + Hierarchy + Roadmap + 10 section hubs)
Remaining scaffolds:    0
Files with no status:   0

✅ CHAPTER 100% COMPLETE
```

## Commit
```
71c8091 Rheumatology: 6 more full notes + hub status normalization - 65/65 (100%)
20 files changed, 3208 insertions(+), 290 deletions(-)
rename Rheumatology/{ => Polymyalgia Rheumatica and Related Disorders}/IgG4-related disease.md (100%)
```
Pushed to `origin main`.

## Cross-Reference Against Davidson 24e Ch 26 TOC
All standard medical school rheumatology curriculum topics from Davidson 24th Edition Chapter 26 (Rheumatology and bone disease) covered:
- ✅ RA, SLE, SSc, Sjögren's, MCTD, myositis, APS, Still's, relapsing polychondritis, Behçet's
- ✅ All crystal arthropathies (gout, CPPD, BCP)
- ✅ All ANCA vasculitides (GPA, MPA, EGPA)
- ✅ Large-vessel vasculitis (GCA, Takayasu)
- ✅ Secondary vasculitides
- ✅ Spondyloarthritis subtypes (AS, PsA, ReA, Enteropathic, Undifferentiated, JIA)
- ✅ Septic arthritis, osteomyelitis, TB arthritis, Lyme, viral arthritis, rheumatic fever
- ✅ Osteoporosis, osteomalacia, Paget's, GIOP, renal osteodystrophy, hyperparathyroidism
- ✅ PMR, GCA, sarcoidosis, IgG4-RD
- ✅ Fibromyalgia, CWP, CRPS
- ✅ All regional soft tissue disorders (shoulder, elbow, hip, knee, foot, CTS, cubital tunnel)
- ✅ Foundational topics: anatomy/physiology, history, examination (GALS), investigations, drugs

**No missing topics detected.**

## Session Insights Encoded as Pitfall 18
See `SKILL.md` Pitfall 18 for:
- 18a. `status: scaffold-hub` false-scaffold trap
- 18b. Overview-file conversion pattern (topic-group → full FCPS/MRCP note)
- 18c. File location must match frontmatter `heading` field
- 18d. 2-part write pattern for 25-35K notes (write_file frontmatter+opener + execute_code append remainder)
- 18e. Status tag naming convention (canonical vs deprecated)
- 18f. Ch 26 audit-verified outcome
- 18g. Web-search validation against Davidson 24e TOC

## Notes for Future Sessions
- The Rheumatology chapter is **complete** — do not rebuild. Only patch on user request.
- The audit script's substring match is a known limitation; future chapters should start with canonical status tags to avoid the false-scaffold trap.
- For chapters with many topic groups, consider building **2-3 overview files per chapter** that integrate children into comparative tables — this is now a validated pattern from Ch 26.
